Financials Shenzhen Chipscreen Biosciences Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
22.2 ^CNY	+0.82%		+7.56%	+1.14%

Apr. 22	Chipscreen Biosciences Offers Sell-Back Option for Microchip Convertible Bond Holders	MT
Apr. 03	Tranche Update on Shenzhen Chipscreen Biosciences Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	23,001	15,174	14,379	8,945	8,945	9,047	-	-
Enterprise Value (EV) ¹	23,001	15,174	14,379	8,945	8,945	9,047	9,047	9,047
P/E ratio	1,087 x	489 x	653 x	511 x	101 x	-56.9 x	-117 x	740 x
Yield	-	-	-	-	-	-	-	-
Capitalization / Revenue	132 x	56.3 x	33.4 x	16.9 x	17.1 x	12.8 x	9.65 x	7.39 x
EV / Revenue	132 x	56.3 x	33.4 x	16.9 x	17.1 x	12.8 x	9.65 x	7.39 x
EV / EBITDA	847 x	311 x	383 x	158 x	63.4 x	-101 x	283 x	63.3 x
EV / FCF	-	-	-	-25.1 x	-23.2 x	-62.8 x	-27.1 x	-27.6 x
FCF Yield	-	-	-	-3.99%	-4.31%	-1.59%	-3.69%	-3.63%
Price to Book	15.9 x	10.2 x	10.1 x	6.49 x	5.69 x	5.89 x	6.2 x	6.15 x
Nbr of stocks (in thousands)	410,000	410,000	410,721	406,971	407,537	407,537	-	-
Reference price ²	56.10	37.01	35.01	21.98	21.95	22.20	22.20	22.20
Announcement Date	2/27/20	2/26/21	2/25/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	173.8	269.5	430.4	529.9	523.7	705	938	1,224
EBITDA ¹	27.16	48.78	37.54	56.64	141	-90	32	143
EBIT ¹	21.67	36.98	22.26	15.97	97.07	-160	-77	16
Operating Margin	12.47%	13.72%	5.17%	3.01%	18.54%	-22.7%	-8.21%	1.31%
Earnings before Tax (EBT) ¹	20.73	36.17	18.6	15.16	97.02	-160	-77	16
Net income ¹	19.42	31.05	21.96	17.48	88.84	-160	-77	13
Net margin	11.17%	11.52%	5.1%	3.3%	16.96%	-22.7%	-8.21%	1.06%
EPS ²	0.0516	0.0757	0.0536	0.0430	0.2176	-0.3900	-0.1900	0.0300
Free Cash Flow ¹	-	-	-	-356.6	-385.9	-144	-334	-328
FCF margin	-	-	-	-67.29%	-73.68%	-20.43%	-35.61%	-26.8%
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share	-	-	-	-	-	-	-	-
Announcement Date	2/27/20	2/26/21	2/25/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow ¹	-	-	-	-357	-386	-144	-334	-328
ROE (net income / shareholders' equity)	2.41%	2.12%	0.02%	1.19%	5.47%	-10.3%	-5.2%	0.9%
ROA (Net income/ Total Assets)	1.15%	-	-	0.72%	2.91%	-4.6%	-1.8%	0.3%
Assets ¹	1,691	-	-	2,414	3,050	3,478	4,278	4,333
Book Value Per Share ²	3.530	3.640	3.450	3.390	3.860	3.770	3.580	3.610
Cash Flow per Share ²	-0.0600	0.2300	0.3000	0.1100	-0.3800	0.1100	0.1900	0.3500
Capex ¹	133	336	288	400	229	172	394	435
Capex / Sales	76.54%	124.79%	67.01%	75.46%	43.65%	24.4%	42%	35.54%
Announcement Date	2/27/20	2/26/21	2/25/22	2/27/23	2/23/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

22.2 CNY

Average target price

26.33 CNY

Spread / Average Target

+18.60%

	1st Jan change	Capi.
SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.	+1.14%	1.25B
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B